MTP-PE

MTP-PE

Pharmacology A synthetic lipophilic analog of the bacterial cell wall component, muramyl dipeptide, that is 'bundled' in fat, in a liposomal vesicle and delivered into the pulmonary vasculature, theoretically triggering the tumorilytic machinery of the pulmonary macrophages; MTP-PE has been evaluated for managing metastatic osteosarcoma
References in periodicals archive ?
When encapsulated in liposomes, MTP-PE is delivered selectively to macrophages via the scavenger lipoprotein receptor pathway.
This includes MTP-PE, recently licensed from Ciba-Geigy Limited and currently in a randomized Phase III clinical trial conducted by the National Cancer Institute as a therapy for osteogenic sarcoma in children.
The potential survival and quality of life benefits for patients treated with L-MTP-PE continue to be supported through physician experience and we remain committed to advancing L- MTP-PE through the European and U.